Halozyme Therapeutics 将以 7.5 亿美元 upfront 收购 Elektrofi

Halozyme Therapeutics 已签订合并协议和计划，以 7.5 亿美元现金 upfront 支付收购 Elektrofi，并额外最多三个 5000 万美元里程碑付款，取决于产品监管批准。该收购需满足 customary closing conditions，包括反垄断审查。

关键事实

申报时间: 2025年10月3日 20:51
事件: 其他
方向: 中性
公司: HALOHalozyme
来源: SEC 8-K
可信度: 有来源

来源摘录

8-K false 0001159036 0001159036 2025-09-30 2025-09-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 12390 El Camino Real San Diego California 92130 (Address of principal executive offices) (Zip Code) (858) 794-8889 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the ap

SEC 8-K